Understanding how duloxetine works for fibromyalgia
Duloxetine Metabolism and Fibromyalgia
This study is trying to see how genetic differences affect how well duloxetine works for people with fibromyalgia, so doctors can better tailor treatments for each patient.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT06866444 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the variability in response to duloxetine treatment among patients with fibromyalgia. It focuses on the relationship between genetic factors that influence drug metabolism and the effectiveness of duloxetine in alleviating symptoms. By analyzing blood concentrations of duloxetine and the genetic variants of drug-metabolizing enzymes, the study seeks to identify which patients are likely to benefit from this medication. The findings could lead to more personalized treatment plans for fibromyalgia patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with fibromyalgia and are currently taking duloxetine at a dosage of 60 mg/day for at least 8 weeks.
Not a fit: Patients who may not benefit from this study include those with progressive illnesses other than fibromyalgia that involve chronic pain and fatigue, as well as individuals with kidney or liver dysfunction.
Why it matters
Potential benefit: If successful, this study could help identify which patients are most likely to benefit from duloxetine, leading to more effective and personalized treatment strategies for fibromyalgia.
How similar studies have performed: While there have been studies exploring the pharmacogenomics of duloxetine, this specific approach focusing on fibromyalgia treatment response variability is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults 18+ * Meeting diagnostic criteria for Fibromyalgia * Patients taking Duloxetine 60 mg/day for at least 8 weeks Exclusion Criteria: * Pregnant patients per verbal confirmation * Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis. * Patients requiring an interpreter to communicate * Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).
Where this trial is running
Salt Lake City, Utah
- Pain Management Center and Pain Research Center at the University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Jake Steenblick, DNP — University of Utah
- Study coordinator: Jake Steenblick, DNP
- Email: jacob.steenblik@nurs.utah.edu
- Phone: 801-585-1216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.